ISS backs election of Langer to replace former Biogen director Denner
By Svea Herbst-Bayliss NEW YORK (Reuters) – Proxy advisory firm Institutional Shareholder Services on Thursday recommended that Biogen shareholders elect Susan Langer to replace long-standing director Alex Denner, who abruptly left…
Former J&J executive emerges as front-runner for Biogen top job – STAT News
(Reuters) – Mathai Mammen, a former executive at drugmaker Johnson & Johnson, has emerged as a top candidate to head Biogen as chief executive officer, news website STAT reported on Friday, citing…
Biogen Inc. Agrees to Pay $900 Million to Settle False Claims Act Allegations Related to Improper Physician Payments
BOSTON – Pharmaceutical company Biogen Inc. (Biogen), based in Cambridge, Massachusetts, has agreed to pay $900 million to resolve allegations that it violated the False Claims Act by causing the submission of…
Biogen CEO to leave as Alzheimer’s drug struggles
(Reuters) – Biogen said on Tuesday its Chief Executive Michel Vounatsos will step down, with the drugmaker adding it would scale down its sales infrastructure for the controversial Alzheimer’s drug Aduhelm. Below…
Alzheimer’s patient groups pressure U.S. to pay for Biogen drug
By Deena Beasley – Patient groups are mounting a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s treatments, spending millions of dollars on television…
REPORT: Biogen, Eisai Began Application For Alzheimer’s Drug
Biogen, and its Japanese partner Eisai, announced Monday that it plans to begin the process for U.S. approval for its experimental drug for Alzheimer’s. Biogen and Eisai announced “rolling submission” to the…
Breaking News
